Related Experiment Video
Updated: May 22, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Do the British public recognise differences in survival between three common cancers?
K L Whitaker1, A E Simon, R J Beeken
1Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, UK.
British Journal of Cancer
|May 5, 2012
Summary
The British public understands that survival rates differ among breast, colorectal, and lung cancers. Awareness of these cancer survival differences was consistent across demographics.
Area of Science:
- Oncology
- Public Health
- Cancer Research
Background:
- Cancer is recognized as a complex disease with varying causes and progression.
- Public awareness regarding differences in cancer types and prognoses remains largely unexplored.
- This study investigates public perception of survival rates for common cancers.
Purpose of the Study:
- To assess British adults' awareness of survival differences between breast, colorectal, and lung cancers.
- To evaluate public perception of curability for these three common cancers.
- To determine if demographic factors influence awareness of cancer survivability.
Main Methods:
- A population-based survey was conducted using home interviews with 2018 participants.
- Respondents provided quantitative (numeric) estimates of 5-year survival for each cancer.
- Respondents also answered qualitative (non-numeric) questions regarding cancer curability.
Main Results:
- Participants correctly perceived that 5-year survival rates are higher for breast cancer than colorectal cancer (CRC), and higher for CRC than lung cancer.
- Perceived curability followed the same pattern: breast cancer > colorectal cancer > lung cancer.
- Awareness of these survival and curability differences was consistent across sex, age, and socioeconomic status.
- A trend of underestimating breast cancer survival and overestimating lung cancer survival was observed.
Conclusions:
- The British public demonstrates an understanding that cancer fatality rates are not uniform.
- Public perception aligns with established differences in survival rates for common cancers.
- Further research may explore the nuances of public perception regarding specific cancer prognoses.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...